Investor Presentaiton
Hematology
Reblozyl BET Inhibitor Breyanzi golcadomide Abecma
alnuctamab
GPRC5D
iber/mezi
Expanding Targeted Protein Degradation into lymphoma
Unmet Need in 1L LBCL: High-risk disease defined based on the IPI, where R-CHOP leads to cure in less patients
Overall response rate, %
High response rates seen with golcadomide + R-CHOP in 1L DLBCL1
100
ORR, 100%
80
67%
60
60
60
40
40
20
20
33%
0
All Dose Levels
(n=15)
CR, 100%
.
CR
•
100
PR
Dose Level 1
0.4 mg day 1-7
(n=7)
Manageable Safety Profile1
No new safety signals were
observed with golcadomide
monotherapy
Golcadomide was safely combined
with rituximab, with no DLTs
observed
• Golcadomide has good
combinability with R-CHOP, with
manageable safety profile
Plan to initiate 1L LBCL registrational trial in 2024
Data anticipated 2027+
1. Munoz J, et al. ICML 2023 (poster #438).
Ill Bristol Myers Squibb™
Not for Product Promotional Use
80View entire presentation